Rate This Document

A Response to FDA Perspective on Approaches for Complying with CGMPS During Phase I INDs Draft Guidance for Industry

• Description: by Barry Friedman, PhD, Director, Quality Control, Cambrex Bio Science-Baltimore
• Published on: Nov 16, 2023
• Rating Period:

Rate this document Average rating:

()

★

Newest on top Oldest on top

Load more reviews

Rating

Your name

Email (optional)

New code

Please type the code above

Submit

Your rating for this document has already been submitted

Login to be able to write a review

|

()